## IAP15 Rec'd PCT/PTO 07 APR 2006

## Confirmation No.

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet

Complete if Known Substitute for form 1449/PTO Application Number Filing Date INFORMATION DISCLOSURE First Named Inventor Kazuo Ando, et al STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number PC26145A

	•		U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code		riguics Appear	
/CC/		<sup>US-</sup> 5,710,168	01-20-1998	Bertrand L. Chenard	
		US-			
		US-			
· · ·		US-			
		US-			
		US-			
		US-			-
		US-			
		US-	<u> </u>		
-		US-			
		US-			

Examiner Initials*	Cite No.1		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	110.	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of older postment	Or Relevant Figures Appear	T⁵
/CC/		WO1996/06081 A1	02-29-1996	Pfizer Inc		
/CC/		WO 1997/23216 A1	07-03-1997	Warner-Lambert Co.		
/CC/		WO 1999/21539 A1	05-06-0199	Warner-Lambert Co.		
						┾
						╄

Examiner Signature	/Celia Chang/	Date Considered	12/10/2008	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## IAP15 Rec'd PCT/PTO 07 APR 2006

Confirmation No.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known				
Substitut	e lot lottil (445/P1O			Application Number		10/5753	583	
INFO	ORMATION	DIS	CLOSURE	Filing Date				
STATEMENT BY APPLICANT				First Named Inventor	Kazuo Ando, et al.			
	***			Art Unit				
	(Use as many she	ets as ne	ecessary)	Examiner Name				
Sheet	2	of	3	Attorney Docket Number	PC26145A	·	フ	

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/CC/		S. BOYCE, et al., "Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn " Neurpharmacology, 199, pp 611-623, Vol. 38, No. 5	
***************************************		I CAVERO, et al., "Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias", Expert Opinion on Pharmacotherapy, 2000, pp 947-973, Vol. 1, No. 5	
***************************************		K. FINLAYSON, et al., "[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen", Euro J Pharmacology, 2001, pp 147-148, Vol. 430, No. 1	
0)0000000000000000000000000000000000000		D. M. GRENNAN, et al., "Rheumatoid Arthritis", Textbook of Pain, 1994, pp 397-407	
000000000000000000000000000000000000000		J. H. HOGUE, et al., "Pathophysiology and First-Line Treatment of Osteoarthritis", The Annals of Pharmacotherapy, 2002, pp 679-686, Vol. 36	
0,0000000000000000000000000000000000000		J. LEVINE, et al., "Inflammatory Pain", Textbook of Pain, 1994, pp 45-56	
000000000000000000000000000000000000000		C. MCCARTHY, et al., "Osteoarthritis", Textbook of Pain, 1994, pp 387-396	
000000000000000000000000000000000000000		R. A. MEYER, et al., "Peripheral Neural Mechanisms of Nociception", Textbook of Pain, 1994, pp 13-55	
200000000000000000000000000000000000000		M. J. MILLAN, et al., "The Induction of Pain: An Integrative Review", Progress in Neurobiology, 1999, pp 1-64, Vol. 57	
/CC/		C. J. WOOLF, et al., "Implications of Recent Advances in the Understanding of Pain Pathophysiology for the Assessment of Pain in Patients", Pain Supplement, 1999, pp S141-S147, No. 6	<del></del>

Examiner	(Calia Chana/	Date	10/10/0000
Signature	/Celia Chang/	Considered	12/10/2008

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## IAP15 Rec'd PCT/PTO 07 APR 2006

Confirmation No.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT **First Named Inventor** Kazuo Ando, et al. Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number Sheet 3 3 PC26145A of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/CC/		C. J. WOOLF, et al., "Neuronal Plasticity: Increasing the Gain in Pain", Science, 2000, pp 1765-1768, Vol. 288	
/CC/		C. J. WOOLF, et al., "Neuropathic pain:aetiology, symptoms, mechnisms, and management", The Lancet, 1999, pp 1959-1964, Vol. 353, No. 9168	

Examiner	/Calia Ohana/	Date	12/10/2008
Signature	/Celia Chang/	Considered	12/10/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.